Aishwarya S. Babu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Aishwarya S. Babu has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Akhilesh Pandey
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
2 shared publications - Parthasarathy Ponnusamy
Manipal Academy of Higher Education, Manipal, Karnataka, India
2 shared publications - Renu Verma
Manipal Academy of Higher Education, Manipal, Karnataka, India
2 shared publications Deepak Murthy
Vivekananda Memorial Hospital, Swami Vivekananda Youth Movement, Saragur, Mysuru, Karnataka, India
1 shared publication- Ellappan Kalaiarasan
Department of Microbiology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India
1 shared publication - Kumar Gavali Suryanarayana
Vivekananda Memorial Hospital, Swami Vivekananda Youth Movement, Saragur, Mysuru, Karnataka, India
1 shared publication
Latest Publications
- Open Access
IMPACT OF CENTRALIZED NIKSHAY ON TB NOTIFICATION AND DATA COMPLETENESS IN INDIGENOUS TRIBES: A 21-YEAR STUDY
BACKGROUND: Indigenous tribes face a disproportionately high tuberculosis (TB) burden due to deep-rooted socioeconomic disadvantage, highlighting the need for strengthened surveillance and control strategies. METHODS: We conducted a 21-year retrospective study (2005-2025) among tribal and neighboring non-tribal populations attending a tribal-serving hospital in Karnataka. Pre-Nikshay data were transcribed from paper registers, and post-Nikshay data were obtained from the digital system. We assessed negative binomial interrupted time-series regression model, data completeness, TB risk factors, and used multivariable logistic regression to identify determinants of poor treatment outcomes and household contact screening yield. RESULTS: We analyzed 1,512 TB cases (tribal = 1,021; non-tribal = 491). TB detection increased significantly over time, with a steeper rise among tribal populations (pp p =0.029) was independently associated with poor treatment outcome. Among 503 index cases, 1,535 household contacts were identified and 1,161 (75.6%) screened; coverage was lower among tribal contacts (69.8% vs 87.2%; p<0.001). CONCLUSIONS: Nikshay strengthened TB surveillance and improved assessment of TB burden and risk factors in tribal communities.
Open AccessIMPACT OF CENTRALIZED NIKSHAY ON TB NOTIFICATION AND DATA COMPLETENESS IN INDIGENOUS TRIBES: A 21-YEAR STUDY
BACKGROUND: Indigenous tribes face a disproportionately high tuberculosis (TB) burden due to deep-rooted socioeconomic disadvantage, highlighting the need for strengthened surveillance and control strategies. METHODS: We conducted a 21-year retrospective study (2005-2025) among tribal and neighboring non-tribal populations attending a tribal-serving hospital in Karnataka. Pre-Nikshay data were transcribed from paper registers, and post-Nikshay data were obtained from the digital system. We assessed negative binomial interrupted time-series regression model, data completeness, TB risk factors, and used multivariable logistic regression to identify determinants of poor treatment outcomes and household contact screening yield. RESULTS: We analyzed 1,512 TB cases (tribal = 1,021; non-tribal = 491). TB detection increased significantly over time, with a steeper rise among tribal populations (pp p =0.029) was independently associated with poor treatment outcome. Among 503 index cases, 1,535 household contacts were identified and 1,161 (75.6%) screened; coverage was lower among tribal contacts (69.8% vs 87.2%; p<0.001). CONCLUSIONS: Nikshay strengthened TB surveillance and improved assessment of TB burden and risk factors in tribal communities.
- Open Access
Direct detection and quantification of Mycobacterium tuberculosis from clinical samples by high-resolution melt qPCR
Background: Estimating bacterial load in clinical samples has important applications in tuberculosis (TB) management, including assessment of disease severity, treatment response, and baseline genome copies required for sequencing. However, rapid and affordable tools for quantifying Mycobacterium tuberculosis ( M. tuberculosis ) remain limited. Methods: We developed a high-resolution melt (HRM) based quantitative PCR assay using molecular beacon chemistry targeting the single-copy RD9 region of M. tuberculosis . Analytical performance was assessed using 10-fold serial dilutions of H37Rv DNA. Clinical validation included DNA from 100 M. tuberculosis culture isolates and 40 sputum samples from Xpert MTB/RIF- and culture-positive pulmonary TB patients. To evaluate specificity, we tested 30 non-tuberculous mycobacterium (NTM) culture isolates from patients infected with Mycobacterium abscessus (n=25) and Mycobacterium fortuitum (n=5) and DNA from saliva samples of 10 healthy controls. Results: The HRM-qPCR assay showed a linear dynamic range from 10 1 to 10 6 genome copies per reaction, with a lower limit of detection of 10 copies. Standardized melt-curve analysis yielded a single target-specific peak at 73.7±0.12°C across dilutions, confirming specific amplification. Sensitivity for M. tuberculosis detection was 100% in culture isolates and 95.0% (38/40) in sputum, with no false positives among M. tuberculosis -negative controls. Assay specificity was 100% in both culture isolates and sputum, with no additional melt peaks. We did not observe any peaks indicative of non-specific binding in NTMs. Amplification was observed in two NTM samples whose Tm matched M. tuberculosis RD9 (median M. tuberculosis copies=678.5), suggesting possible co-infection or contamination. No amplification or specific melt peaks were observed in saliva samples, indicating high probe specificity. Conclusions: Molecular beacon-based HRM-qPCR assay enables rapid, highly specific quantification of M. tuberculosis genome copies in clinical samples and has potential utility for treatment monitoring, triaging specimens for sequencing, and assessing transmission risk in high-burden settings.
Open AccessDirect detection and quantification of Mycobacterium tuberculosis from clinical samples by high-resolution melt qPCR
Background: Estimating bacterial load in clinical samples has important applications in tuberculosis (TB) management, including assessment of disease severity, treatment response, and baseline genome copies required for sequencing. However, rapid and affordable tools for quantifying Mycobacterium tuberculosis ( M. tuberculosis ) remain limited. Methods: We developed a high-resolution melt (HRM) based quantitative PCR assay using molecular beacon chemistry targeting the single-copy RD9 region of M. tuberculosis . Analytical performance was assessed using 10-fold serial dilutions of H37Rv DNA. Clinical validation included DNA from 100 M. tuberculosis culture isolates and 40 sputum samples from Xpert MTB/RIF- and culture-positive pulmonary TB patients. To evaluate specificity, we tested 30 non-tuberculous mycobacterium (NTM) culture isolates from patients infected with Mycobacterium abscessus (n=25) and Mycobacterium fortuitum (n=5) and DNA from saliva samples of 10 healthy controls. Results: The HRM-qPCR assay showed a linear dynamic range from 10 1 to 10 6 genome copies per reaction, with a lower limit of detection of 10 copies. Standardized melt-curve analysis yielded a single target-specific peak at 73.7±0.12°C across dilutions, confirming specific amplification. Sensitivity for M. tuberculosis detection was 100% in culture isolates and 95.0% (38/40) in sputum, with no false positives among M. tuberculosis -negative controls. Assay specificity was 100% in both culture isolates and sputum, with no additional melt peaks. We did not observe any peaks indicative of non-specific binding in NTMs. Amplification was observed in two NTM samples whose Tm matched M. tuberculosis RD9 (median M. tuberculosis copies=678.5), suggesting possible co-infection or contamination. No amplification or specific melt peaks were observed in saliva samples, indicating high probe specificity. Conclusions: Molecular beacon-based HRM-qPCR assay enables rapid, highly specific quantification of M. tuberculosis genome copies in clinical samples and has potential utility for treatment monitoring, triaging specimens for sequencing, and assessing transmission risk in high-burden settings.